JDRF One Walk Preview

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

Gayle Anderson was live in Pasadena with a preview of Saturday’s JDRF One Walk.

November is National Diabetes Awareness Month! Diabetes is the name given to disorders in which the body has trouble regulating its blood-glucose, or blood-sugar, levels. There are two major types of diabetes: Type 1 and Type 2.

Type 1 diabetes (T1D) is an autoimmune disease in which a person’s pancreas loses the ability to produce insulin – a hormone essential to turning food into energy. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. While the causes of T1D are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. Its onset has nothing to do with diet or lifestyle. Additionally, it is a disease that cannot be prevented or cured.

More than 15,000 children and 15,000 adults in the United States receive a Type 1 diabetes diagnosis each year. As many as 3 million Americans may have T1D. While insulin injections or infusion allow a person with T1D to stay alive, they do not cure the disease, nor do they necessarily prevent the possibility of the disease’s serious side effects, which may include kidney failure, blindness, nerve damage, heart attack, stroke, and pregnancy complications.

While there is not a cure for T1D yet, Selecta Bioscience , a clinical stage biotechnology company, has been developing nanoparticles called Synthetic Vaccine Particle (SVP) as an immunotherapy for Type 1 diabetes (T1D) with support from JDRF. Using this funding, Selecta will test the ability of SVP to prevent T1D in diabetic mice. The vaccine is expected to act by re-programming the immune system to prevent the destruction of insulin-producing beta cells. Courtesy JDRF.com.

Additionally, researchers from the University of Alabama, Birmingham, found the common blood pressure drug verapamil, completely reversed Type 1 diabetes in mice. They expect to test the drug on humans next year. ( Courtesy MedicalDaily.com )

To help raise awareness and fund research on Type 1 diabetes, the Los Angeles Chapter of JDRF is hosting the JDRF ONE WALK  Saturday, November 15, 2014 from 8 a.m. to 1 p.m. Each year, JDRF ONE WALK brings together more than 900,000 people and has raised $1 billion to date to help fund scientific research on T1D. While there is not a registration fee to sign up, participants are encouraged to support the walk by fundraising or making a donation to JDRF. Click HERE to register for the walk or donate to JDRF.

JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF is currently sponsoring $568 million in scientific research in 17 countries. In 2012 alone, JDRF provided more than $110 million to T1D research. JDRF’s goal is to progressively remove the impact of T1D from people’s lives until it achieves a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. For more information, click HERE.
Saturday, November 15, 2014
Los Angeles JDRF One Walk
Rose Bowl
1001 Rose Bowl Drive
Pasadena, CA 91103

JDRF Los Angeles Chapter
811 Wilshire Boulevard, Suite 1600
Los Angeles, CA 90017
(213) 233-9901
(213) 622-6276 FAX

JDRF
26 Broadway
New York, NY 10004
(800) 533-CURE (2873)
(212) 785-9595

 

 

-0-

 

If you have questions, please feel free to call Gayle Anderson at 323-460-5732 or e-mail Gayle at Gayle.Anderson@KTLA.com